NCT03045393View on ClinicalTrials.gov

Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

April 17, 2017

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions

Breast Cancer Triple Negative

Interventions

DRUG

Mirvetuximab Soravtansine (IMGN853)

Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Comprehensive Cancer Network

NETWORK

lead

Duke University

OTHER